Abstract
The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)
| Original language | English |
|---|---|
| Pages (from-to) | 193-198 |
| Number of pages | 6 |
| Journal | American Journal of Hypertension |
| Volume | 15 |
| Issue number | 2 I |
| DOIs | |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- Cardiovascular morbidity and mortality
- Isolated systolic hypertension
- Omapatrilat
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial. / Kostis, John B.; Cobbe, Stuart; Johnston, Colin; Ford, Ian; Murphy, Michael; Weber, Michael A.; Black, Henry R.; Plouin, Pierre Francois; Levy, Daniel; Mancia, Guiseppe; Larochelle, Pierre; Kolloch, Rainer E.; Alderman, Michael; Ruilope, Luis Miguel; Dahlöf, Björn; Flack, John M.; Wolf, Robert.
In: American Journal of Hypertension, Vol. 15, No. 2 I, 2002, p. 193-198.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial
AU - Kostis, John B.
AU - Cobbe, Stuart
AU - Johnston, Colin
AU - Ford, Ian
AU - Murphy, Michael
AU - Weber, Michael A.
AU - Black, Henry R.
AU - Plouin, Pierre Francois
AU - Levy, Daniel
AU - Mancia, Guiseppe
AU - Larochelle, Pierre
AU - Kolloch, Rainer E.
AU - Alderman, Michael
AU - Ruilope, Luis Miguel
AU - Dahlöf, Björn
AU - Flack, John M.
AU - Wolf, Robert
PY - 2002
Y1 - 2002
N2 - The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)
AB - The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)
KW - Cardiovascular morbidity and mortality
KW - Isolated systolic hypertension
KW - Omapatrilat
UR - http://www.scopus.com/inward/record.url?scp=0036175311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036175311&partnerID=8YFLogxK
U2 - 10.1016/S0895-7061(01)02048-9
DO - 10.1016/S0895-7061(01)02048-9
M3 - Article
VL - 15
SP - 193
EP - 198
JO - American Journal of Hypertension
JF - American Journal of Hypertension
SN - 0895-7061
IS - 2 I
ER -